drugset / Trial / NCT00367952
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial
Timeline
- Start
- 2006-08
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | apricitabine | Small molecule | 800 mg | Oral |